VS3 Medical

Executive Summary

VS3 Medical is a privately held medical device company dedicated to addressing symptomatic venous sinus stenosis (VSS), a condition affecting the brain's venous drainage system that can lead to debilitating pulsatile tinnitus and headaches. The company's lead product, the VS3 Medical Stent System, is an investigational device engineered to conform to the unique anatomy of the dural venous sinuses, aiming to restore normal blood flow and alleviate symptoms. Founded in 2020 and headquartered in San Diego, VS3 Medical is positioned to fill a critical gap in the treatment of VSS, which currently lacks optimized interventional solutions. As an early-stage company, VS3 Medical's progress hinges on successful clinical validation and regulatory milestones. The stent system's design offers potential advantages over generic neurovascular stents by specifically addressing the large, curved venous anatomy. With no approved stent indicated for VSS, the market opportunity is substantial. Key upcoming milestones include regulatory clearances and initial clinical data, which could catalyze investor interest and strategic partnerships. The company's innovative approach and clear unmet need underpin its potential for growth and eventual market entry.

Upcoming Catalysts (preview)

• Q3 2026FDA IDE Approval for First-in-Human Study60% success
• Q4 2026Initiation of First-in-Human Clinical Trial50% success
• Q2 2026Series A Financing Round Completion70% success